Glaucoma is the cause of visual impairment or blindness in four percent of the total number of patients in the Netherlands1. Among these, primary open-angl...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be ...
Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $...
Roivant (Nasdaq: ROIV) announced the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upf...
In addition, Lonza, Medivir's partner for process development and manufacture of drug substance, has developed a process suitable for commercial manufactur...
Macrogen Europe is seeking to expand within Switzerland from its foothold in Basel with its Sanger sequencing laborato...
The significant milestone marks the first result of the company's strategic partnership2 with VIB, Flanders' leading life sciences institute, and potential...
RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) dedicated to developing therapies for patients w...
Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium ...
As a result, Vetter has committed to the 1.5 degrees of global warming target. To this end, the CDMO has presented a sustainability strategy with concrete ...
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to ...
Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inh...
Pimicotinib (ABSK021) is currently in a global Phase III study in tenosynovial giant cell tumor (TGCT) Merck to receive an exclusive commercial license ...
© 2025 Biopharma Boardroom. All Rights Reserved.
